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Abstract
Purpose: The antineoplastic efficacy of anthracyclines is limited by their cardiac toxicity. In this study, we evaluated the
toxicity of doxorubicin, non-pegylated liposomal-delivered doxorubicin, and epirubicin in HL-1 adult cardiomyocytes in
culture as well as in the mouse in vivo.
Methods: The cardiomyocytes were incubated with the three anthracyclines (1 mM) to assess reactive oxygen generation,
DNA damage and apoptotic cell death. CF-1 mice (10/group) received doxorubicin, epirubicin or non-pegylated liposomal-
doxorubicin (10 mg/kg) and cardiac function was monitored by Doppler echocardiography to measure left ventricular
ejection fraction (LVEF), heart rate (HR) and cardiac output (CO) both prior to and 10 days after drug treatment.
Results: In HL-1 cells, non-pegylated liposomal-doxorubicin generated significantly less reactive oxygen species (ROS), as
well as less DNA damage and apoptosis activation when compared with doxorubicin and epirubicin. Cultured breast tumor
cells showed similar sensitivity to the three anthracyclines. In the healthy mouse, non-pegylated liposomal doxorubicin
showed a minimal and non-significant decrease in LVEF with no change in HR or CO, compared to doxorubicin and
epirubicin.
Conclusion: This study provides evidence for reduced cardiac toxicity of non-pegylated-liposomal doxorubicin
characterized by attenuation of ROS generation, DNA damage and apoptosis in comparison to epirubicin and doxorubicin.
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Introduction
Advances in the treatment of cancer improved cancer-free
survival and unfortunately highlighted the occurrence of previ-
ously unrecognized complications such as secondary neoplasms
and off-target organ toxicity [1–4]. The potent anti-cancer effects
of anthracyclines are limited by their cardiac toxicity [5].
Doxorubicin and epirubicin are the most commonly used
anthracyclines [5–7]. Doxorubicin produces a dose-dependent
increased risk of cardiomyopathy, heart failure and arrhythmias
[6,8] probably promoted by apoptotic cardiomyocyte cell death
[9–12]. Epirubicin has been proposed as an alternative to
doxorubicin because of reportedly lesser cardiac toxicity [8]. A
novel liposomal-delivered doxorubicin formulation (MyocetTM),
which has been introduced recently, has also been associated with
reduced cardiac toxicity [8]. One clinical study has suggested that
epirubicin and liposomal doxorubicin have similar cardiotoxic
profiles [13]. The LITE study [Liposomal doxorubicin–Investiga-
tional chemotherapy–Tissue doppler imaging] is another recently
completed clinical trial in patients with breast cancer randomized
to a non-pegylated liposomal-doxorubicin-based or epirubicin-
based chemotherapy regimen to determine the incidence of
clinical and subclinical cardiotoxicity using Tissue Doppler
Analysis [14,15].
To better characterize the mechanisms of cardiotoxicity and the
differences between the three anthracyclines, we evaluated the
effects of a non-pegylated liposomal-delivered doxorubicin formu-
lation in comparison with standard doxorubicin as well as
epirubicin on cardiomyocytes in culture in vitro and on cardiac
systolic function, heart rate (HR) and cardiac output (CO) in the
mouse in vivo.
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Methods
Cell Lines and Drug Treatments
HL-1 adult cardiomyocytes [16] were kindly donated by Dr.
Claycomb (Louisiana State University, New Orleans, Louisiana)
and cultured in Claycomb medium (Sigma-Aldrich, Saint Louis,
Missouri) according to the manufacturer’s suggestions.
MCF-7 cells, a breast cancer cell line, were used to test the anti-
tumor effects of the anthracyclines. The cells were maintained at
37uC in 5% CO2 supplemented humified atmosphere in 1640
RPMI (GIBCO, Grand Island, NY) supplemented with 5% FBS
(Gemini Bio Products, Sacramento, CA), 5% BCS (Hyclone
Laboratories, Logan, Utah) and 1X Penicillin/Streptomycin
(GIBCO).
In HL-1 cells, non-pegylated liposomal-delivered doxorubicin
(Cephalon, Rome, Italy), doxorubicin and epirubicin (Tocris,
Saint Louis, Missouri) were tested at 1 mM. In MCF-7 cells,
anthracyclines were used at concentrations between 0.1 and 5 mM.
Reactive Oxygen Species Generation
HL-1 cells were plated at a density of 16104 cells/well in 96
well plates. Reactive oxygen species (ROS) were detected using
29,79-dichlorofluorescein di-acetate (10 mM). The probe was
incubated 1 hour before treatments with the anthracyclines and
fluorescence was read after 20 minutes at 560 nm in a Glomax
reader (Promega, Madison, WI). ROS generation was reported as
the-fold increase in fluorescence compared to the untreated
control. Experiments were performed in triplicate and the data
reported represents the average of the measurements collected.
Induction of DNA Double-strand Breaks
HL-1 cells were used to assess the entity of DNA damage
induced by the three anthracyclines in adult cardiomyocytes.
H2AX phosphorylation at the serine 138 (gamma-H2AX) was
used as marker of early (2 hours) DNA double-strand breaks [17].
HL-1 cells were plated onto 8 wells multi-well glasses and then
exposed to anthracyclines for 2 hours, washed twice in ice-cold
PBS and fixed in 1% formalin. An Alexa fluor mouse anti-
gammaH2AX (BD Biosciences) was used to mark the DNA
double-strand breaks positive nuclei and 49,69-diamidino-2-
phenylindole (DAPI, GIBCO) was used to stain all the nuclei.
The cells were analyzed using a Zeiss LSM 710 confocal
microscope; quantification of cells with double-strand DNA breaks
was expressed as average number of gamma-H2AX foci per cell.
Caspase-3 Activity by Western Blotting
HL-1 cells were exposed to the anthracyclines for 24 hours and
then harvested and lysed in RIPA buffer containing a protease
inhibitor cocktail (Sigma Aldrich). Following SDS-PAGE and
blotting onto a nitrocellulose membrane, a rabbit anti-caspase-3
(Cell Signaling, Danvers, MA) was incubated at a 1:1,000 dilution
and probed with a horse-radish peroxidase conjugated goat anti-
rabbit antibody diluted 5,000 times (Santa Cruz Biotechnology,
Santa Cruz, CA) to visualize the protein in combination with
enhanced chemiluminescence. Beta-actin (Santa Cruz Biotechnol-
ogy; 1:5,000 dilution) was used to normalize the protein content.
Quantitative data were obtained from 3 independent experiments
using the Scion Image software (Scion Corporation) and were
expressed as fold increase compared to controls.
Assay for Executioner Caspases-3 and -7 activity
HL-1 cells were exposed to non-pegylated liposomal doxorubi-
cin, doxorubicin, or epirubicin for 24 hours. The Caspase-GLO
assay (Promega) exploits a fluorescent substrate common for
caspase-3 and -7 as measure of activation of the apoptotic pathway
and was used accordingly to the supplier9s instructions. The
activity of the caspase-3 and -7 was expressed as fold change
compared to controls.
Annexin V
Flow cytometry was used to measure the percentage of annexin
V positive HL-1 cells. Briefly, HL-1 cells were treated with the
anthracyclines (1 mM) in quadruplicates. After 24 hours the cells
were harvested, washed twice in ice cold phosphate buffered saline
and fixed in 1% formalin. The staining was performed using the
Annexin V detection kit (BD Bioscience, San Jose, California)
accordingly to the manufacturer instructions. The cells were
analyzed using the BD FACSCanto II flow cytometer (BD
Biosciences). The data are reported as percentage of annexin V
positive cells.
Growth Assay on Breast Cancer Cells
The anti-tumor effects of the three anthracyclines used here on
HL-1 cells, were tested on the breast cancer cell line MCF-7.
86103 MCF-7 cells were seeded in a 96-well plate and following
24 hours of acclimation the cells were challenged with for 48 hours
with 100 nM, 250 nM, 500 nM, 1 mM and 5 mM of doxorubicin,
epirubicin and non-pegylated liposomal-doxorubicin. A growth
assay was performed using the Thiazolyl Blue Tetrazolium
Bromide kit (MTT) (Sigma Aldrich, Saint Louis, MO) accordingly
to the supplier instructions. The results are presented as mean of
the absorbance obtained from 6 repetitions for each dose tested.
Cardiotoxicity in vivo
All animal experiments were conducted under the guidelines on
humane use and care of laboratory animals for biomedical
research published by the US National Institutes of Health. The
Virginia Commonwealth University Institutional Animal Care
and Use Committee approved the study protocol.
CF-1 mice (Charles River Laboratories, Wilmington, Massa-
chusetts) were used to study the effects of the non-pegylated
liposomal doxorubicin, doxorubicin or epirubicin in vivo. Two
month old male mice were injected intraperitoneally (10 each
group) with 10 mg/kg of each drug, while control mice were
injected with an equal volume of 0.9% normal saline.
All animals underwent Doppler echocardiography at baseline
and 10 days after the injection to measure left ventricular systolic
function, heart rate and cardiac output, as previously described
[18] and according to the recommendations of the American
Society of Echocardiography [19]. Briefly, mice were lightly
sedated with sodium pentobarbital (30–50 mg/Kg), shaved and
positioned on a warmed platform to prevent hypothermia. The
VEVO770 machine (Visualsonics, Toronto, Canada) equipped
with a 30 MHz probe was used to measure the left ventricular
(LV) end-diastolic diameter (LVEDD), LV end-systolic diameters
(LVESD) were measured at M-mode. LV fractional shortening
(LVFS) was calculated as [(LVEDD-LVESD)/LVEDD]*100, and
LV ejection fraction (LVEF) was then derived using the Teicholz
formula. Pulsed wave Doppler was used to determine the aortic
valve velocity time interval (VTI) to measure the cardiac output
(CO). The investigators performing and reading the echocardio-
gram were blinded to the treatments.
Statistical Analysis
ANOVA was used for multiple comparisons with post-hoc T-
test to examine group differences. For comparisons of interval
changes between multiple groups random effects ANOVA was
Anthracyclines Cardiac Toxicity
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applied for repeated-measures to determine the main effect of
time, group, and time-by-group interaction. Statistical differences
were considered significant if P values were ,0.05.
Results
In vitro Effects on HL-1 Cells
Reactive oxygen species (ROS) are known to increase in the
cardiomyocytes following exposure to anthracyclines [20]. This
may result in significant damage to cell structures and induction of
apoptosis [20,21]. As expected, the anthracyclines tested induced a
significant increase in ROS generation. In particular, epirubicin
and doxorubicin produced a significantly greater degree of ROS
generation compared to controls (70- and 50-fold respectively) and
compared to the non-pegylated liposomal doxorubicin (20-fold vs
control) (Figure 1).
DNA double-strand breaks were detected as gamma-H2AX foci
[17] by confocal microscopy and representative images are
reported in figure 2 (Panel A). The average number of foci per
nucleus induced by epirubicin, doxorubicin and non-pegylated
liposomal doxorubicin were 67, 84 and 47 respectively (Figure 2B),
a significant increase compared to control cells that had an
average of 7 foci per nucleus (p,0.05). However, the number of
nuclear foci generated in response to the non-pegylated liposomal-
doxorubicin was significantly lower than for the other anthracy-
clines (p,0.05).
Consistent with the patterns observed for ROS production, 24
hours after exposure to the anthracyclines, the cleavage of caspase-
3 induced by epirubicin and doxorubicin (8- and 4-fold vs control)
was significantly higher than non-pegylated liposomal doxorubicin
(2-fold) (Figure 3A). To confirm the results observed on caspase-3
cleavage, we measured the activity of the executioner caspases -3
and -7. Epirubicin and doxorubicin treatments were associated
with higher caspase-3 and -7 activity (9- and 7-fold induction
respectively vs control) compared to the non-pegylated liposomal-
doxorubicin (4-fold increase vs control) (Figure 3B).
Finally, we analyzed extracellular membrane-associated an-
nexin V as an additional marker of apoptosis (Figure 3C). This
assay confirmed the activation of apoptosis, with an increase in
extracellular membrane-linked annexin V of 27%, 21% and 11%
for epirubicin, doxorubicin and non-pegylated liposomal doxoru-
bicin respectively.
Effects of the Anthracyclines on the Growth of a Breast
Cancer Cell Line
In view of the fact that the anthracyclines displayed different
toxicity profiles in the cardiac myocyte studies, it appeared possible
that sensitivity might also be different in tumor cells. To address
this question, we evaluated the effects of different concentrations of
doxorubicin, epirubicin and non-pegylated liposomal-doxorubicin
on the growth of the MCF-7 breast cancer cell line. The MTT
assay, performed 48 hours after exposure of cells to the three
anthracyclines, showed an essentially similar dose-response rela-
tionship for the three drugs (Figure 4).
Cardiotoxicity in vivo
Finally, we tested the effects of the three anthracyclines on
cardiac function in vivo in healthy mice. Ten days after injection
of a single dose, doxorubicin-treated mice had significantly
reduced left ventricular ejection fraction (LVEF), heart rate (HR)
and cardiac output (CO) compared to control mice (p,0.01 vs
control) (Figure 5 and Table1). Epirubicin-treated mice had a
milder decrease in LVEF (p =NS vs control) compared to
baseline, but the impact on HR and CO (p,0.05 vs control)
was similar to that induced by doxorubicin. Mice treated with
non-pegylated liposomal-doxorubicin showed a minimal decrease
in LVEF compared to baseline, and no decrease in HR and CO
(P,0.05 vs doxorubicin), reflecting a lesser degree of cardiac
toxicity than epirubicin and doxorubicin.
Discussion
The use of anthracyclines in the course of cancer treatment is
associated with a 5-fold increased risk of cardiac dysfunction [22].
Previous studies have suggested that epirubicin and liposomal
doxorubicin are associated with reduced cardiotoxicity compared
to doxorubicin [13,15,23]. However, the literature is deficient in
comparative studies designed to assess the cardiotoxic effects of
these three drugs in the same experimental settings and at the
same dose, and therefore proposed mechanistic differences are
often unsupported by direct measurements. The findings of the
present study support the clinical observations of reduced toxicity
of epirubicin and non-pegylated liposomal doxorubicin compared
to doxorubicin and indicate that the differences in cardiotoxicity
are associated with the extent of reactive oxygen generation, DNA
double-strand break induction and apoptosis.
The ‘‘oxidative stress hypothesis’’ of anthracycline-induced
cardiotoxicity explains the damage to the cardiomyocytes based
on the production of ROS that in turn mediate damage to the
DNA and mitochondria, alter calcium flux and gene expression
[20–21,24]. The three anthracyclines formulations tested show
strong increases of ROS after 20 minutes of treatment. However,
ROS induction was significantly attenuated by the liposomal
formulation of doxorubicin. Interestingly, epirubicin induced a
higher increase in ROS compared to doxorubicin, and this
difference, even if not significant, is in contrast with recent findings
of reduced epirubicin effects on ROS production in human
myocardial samples and in the rat cardiomyocyte cell line H9C2
Figure 1. Effects of anthracyclines on reactive oxygen species
production. Cells were treated with the three anthracyclines for 20
minutes prior to determination of reactive oxygen species (ROS). The
graph represents the fluorescence units recorded following each
treatment. Abbreviations list: controlsCtrl; epirubicinEpi; doxorubicin-
Dox; non-pegylated liposomal-doxorubicinLDox. Results are reported as
Mean6Standard Error.
doi:10.1371/journal.pone.0058421.g001
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[25]. This inconsistency could be due to the fact that studies were
performed in a different cell line where HL-1 cells are cultured in a
medium containing norepinephrine. Norepinephrine is known to
increase the metabolism of cardiomyocytes [26–27], which could
be responsible for higher basal oxygen consumption compared to
other in vitro models.
DNA damage induced by the anthracyclines is thought to result
from direct interaction with DNA, inhibition of the enzymes
involved in DNA replication and repair and/or by inducing
indirect damage through ROS [20–21]. Damage to DNA was
assessed by measuring the number of cH2AX positive foci present
in the nuclei of HL-1 cells, where cH2AX is a marker of DNA
double strand breaks associated with phosphorylation of the
histone H2AX on the serine 139 [17]. Two hours after drug
exposure, both doxorubicin and epirubicin induced high and
relatively equal degrees of DNA damage based on the average
number of cH2AX positive foci per nucleus. Consistent with the
ROS data, non-pegylated liposomal-doxorubicin induced less
DNA damage compared to doxorubicin and epirubicin.
Finally we investigated the induction of apoptotic markers since
anthracyclines, ROS generation and DNA damage induce
apoptotic cell death. Caspase-3 is one of the executioner caspases
found to be activated in the anthracycline model of cardiotoxicity
as a consequence of dysfunctional mitochondria producing ROS,
DNA damage or sarcoplasmic reticulum stress [20,24,28]. The
analysis of the cleavage of caspase-3, reflecting its activation, as
Figure 2. Comparative analysis of anthracyclines effects on DNA double strand breaks: phosphorylation of serine 139 of H2AX
(cH2AX). Cells were treated with the anthracyclines for 2 hours. Panel A presents representative images of HL-1 cell nuclei stained for cH2AX. The
nuclei were counterstained with DAPI to detect specific signals and images were collected through confocal microscopy. Light microscopy images
were taken for the field analyzed. Panel B presents the absolute value of the average number of foci detected in each nucleus for each treatment.
Experiment was performed in quadruplicate. Abbreviations list: controlsCtrl; epirubicinEpi; doxorubicinDox; non-pegylated liposomal-doxorubi-
cinLDox. Results are reported as Mean6Standard Error.
doi:10.1371/journal.pone.0058421.g002
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well as measurement of the cleavage of a substrate common to
caspase-3 and caspase-7, showed increases in the anthracyclines
treated groups that paralleled the ROS levels. These findings were
confirmed by analysis of Annexin V, another accepted marker of
apoptosis. In all the three experimental approaches to determine
apoptosis activation we found that non-pegylated liposomal-
doxorubicin possesses a lower cardiotoxic profile. Doxorubicinol
and epirubicinol are toxic secondary metabolites produced from
doxorubicin and epirubicin, respectively. A limitation of this study
is the lack of measurements of these metabolites, as the different
treatments we used could have led to different levels of
doxorubicinol or epirubicinol both in vivo and in vitro. However,
this does not change the central findings here of the paper as we
used the same doses of the drugs in different experimental setting.
Furthermore, as it could be argued that the toxicity of the three
anthracyclines in the cardiomyocyte study might reflect their
Figure 3. Effects of anthracyclines on apoptotic markers in HL-1 cardiomyocytes in vitro. Cells were treated with the anthracyclines for 24
hours. Panel A shows caspase-3 cleavage and a representative densitometric analysis of the active/cleaved caspase-3. Panel B presents a comparison
of the enzymatic activity associated with the cleavage of a substrate common to caspase-3 and caspase-7. Panel C shows the percentage of annexin V
positive cardiomyocytes following anthracycline treatment. Abbreviations list: controlsCtrl; epirubicinEpi; doxorubicinDox; non-pegylated liposomal-
doxorubicinLDox. Results are reported as Mean6Standard Error.
doi:10.1371/journal.pone.0058421.g003
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relative antitumor activities, drug sensitivity was compared in
MCF-7 breast tumor cells. These studies demonstrated that the
three anthracyclines had similar capabilities to suppress breast
tumor cell growth in vitro.
Direct comparisons between epirubicin and liposomal doxoru-
bicin are limited to one small study that included 160 patients with
metastatic breast cancer who were followed for approximately 3
years which showed similar cardiac toxicity between the two drugs
[13] and the LITE study [Liposomal doxorubicin–Investigational
chemotherapy–Tissue doppler imaging], another recently com-
pleted clinical trial in patients with breast cancer randomized to a
non-pegylated liposomal-doxorubicin-based or epirubicin-based
chemotherapy regimen to determine the incidence of clinical and
subclinical cardiotoxicity using Tissue Doppler Analysis [14,15].
Although limited by the small number of subjects and small
changes in LV function, the LITE study suggests a superiority of
the non-pegylated liposomal-doxorubicin-based approach [15].
The current study in the mouse adds to this literature by
characterizing the cardiotoxic effects of the standard doxorubicin
preparation in comparison with both epirubicin and liposomal-
delivered doxorubicin, in terms of ROS production, DNA
damage, and cardiomyocyte apoptosis in cardiomyocyte cell
culture in vitro as well as in the mouse in vivo. We found a
reduction in LVEF that was significantly less with epirubicin and
non-pegylated liposomal-doxorubicin as compared to standard
doxorubicin. Furthermore, we found that epirubicin reduces the
heart rate to a similar degree as doxorubicin while liposomal-
doxorubicin did not depress the heart rate. In animal models of
anthracyclines toxicity, doxorubicin was proven to consistently
induce a reduction in resting heart rate, reflective of damage of the
sinoatrial node [29]. While all three drugs reduced LVEF,
treatment with liposomal doxorubicin led to a modest reduction
in LVEF and a modest increase in heart rate, thereby maintaining
a normal cardiac output, a measure dependent on stroke volume
(CO= [(LVEF x end-diastolic volume) x heart rate]. While this
work analyzed different markers of cardiac toxicity using both
in vitro cultures of adult murine cardiomyocytes and the in vivo
mouse model, we cannot exclude the possibility that the
differences observed between the liposomal formulation of
doxorubicin and standard doxorubicin and epirubicin will prove
to be less dramatic in the clinical setting. Prior studies have shown
that preclinical models, in which significant benefits were observed
with treatments designed to counteract ROS production following
anthracycline therapy failed to translate to the patient population,
leading to a reappraisal of the clinical importance of the oxidative
stress paradigm [19]. One other limitation of our study was to
evaluate the myocardial damage based on echocardiographic
parameters only. The use of markers of myocardial damage as the
serum levels of cardiac troponin T (TnT) or cardiac troponin I
(TnI) may be an alternative technique to assess cardiac damage.
Another possible limitation in our study is the use of a stable cell
line of murine cardiomyocytes. The use of immortalized cell lines
presents both advantages (high reproducibility of data due to the
lower complexity of management compared to primary cells) and
Figure 4. Effects of anthracyclines on growth of MCF-7 breast cancer cells (MTT assay). MCF-7 cells were exposed to increasing doses
(100 nM, 250 nM, 500 nM, 1 mM and 5 mM) of anthracyclines for 24 hours. Absorbance values indicated are proportional to viable cell number.
Abbreviations list: controlsCtrl; epirubicinEpi; doxorubicinDox; non-pegylated liposomal-doxorubicinLDox. Results are reported as Mean6Standard
Error.
doi:10.1371/journal.pone.0058421.g004
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limitations (significant number of changes that may alter their
phenotype compared to the progenitor cells). Replicating cardiac
myocytes are often used to study the cardiotoxic effects of
anthracyclines [30–31] as these models generally express the
majority of cardiac specific genes and have a beating phenotype.
In this study we decided to use mouse-derived adult cardiomyo-
cytes [16] over other cell lines since they origin from the same
species used in the in-vivo experiments. However, cardiomyocytes
represent only one component of cardiac function and future
studies using fibroblasts, endothelial cells may help to collect
additional data on different cardiotoxic profiles of these three
anthracyclines of the heart function. Furthermore, the choice of
the correct animal species or strain is a challenging step since each
animal species or strains may present advantages (size, availability,
and compatibility with the lab instrumentation) and limitations
(genetic variability that could influence the organism response to a
stimulus). We choose CF-1 mice over other strains due to their
extensive use in studies on anthracyclines cardiotoxicity and
because they have a slightly bigger size compared to other mice
(i.e. C57B6), making it easier to assess heart function and
dimensions.
The use of both in vivo and in vitro models helps to overcome
some of the limitations of each model. The in vitro assays were
planned to determine the acute effects of the anthracyclines on the
cardiomyocytes and to assess whether they could corroborate the
chronic in vivo effects. Although there is no evidence of delayed
effects of the non-pegylated liposomal-doxorubicin compared to
the other anthracyclines in vitro and since the mice were followed
for only a 10 days period we cannot exclude the possibility that a
longer period could be necessary for the mice treated with non-
pegylated liposomal-doxorubicin to develop a more severe
cardiomyopathy.
Conclusions
The results presented in this study provide evidence of reduced
cardiac toxicity of non-pegylated-liposomal doxorubicin associated
with attenuation of ROS generation, DNA damage and apoptosis
in comparison to epirubicin and doxorubicin.
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Figure 5. Interval changes in left ventricular ejection fraction (LVEF), heart rate (HR) and cardiac output (CO) in the hearts of mice
treated with anthracyclines. CF-1 mice (N= 10/group) were treated with a single intraperitoneal dose of 10 mg/kg of epirubicin, doxorubicin,
non-pegylated liposomal-doxorubicin (L-Doxorubicin) or a matching volume of vehicle-solution (0.9% NaCl). The changes in LVEF, HR and CO were
recorded 10 days following treatment and the results are reported as percentage change compared to baseline values and expressed as
Mean6Standard Error.
doi:10.1371/journal.pone.0058421.g005
Table 1. Echocardiographic parameters.
Group LVEF (%) HR (bpm) CO (ml/min)
Control 7162 367617 12.568
Epirubicin 6562 288630 11.961.6
Doxorubicin 5463 29768 9.160.3
Non-pegylated liposomal
doxorubicin
6162 419636 17.062.3
Abbreviations: LVEF = Left Ventricular Ejection Fraction; HR =Heart Rate;
CO=Cardiac output; bpm=beats per minute;ml/min =milliliters/minute.
doi:10.1371/journal.pone.0058421.t001
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